为了给予更有价值的信息，本文按博士、硕士、本科三大学历，分别梳理出今年来收益前十的基金经理，供投资者参考。 截至9月15日，3872位公募基金经理中，拥有硕士学历的基金经理高达3375位，占比高达87.16%，其次博士基金经理有377位，本科基金经理仅105位。那 么，不同学历基金经理在管的基金产品，今年来业绩如何？学历越高是否所管理的基金产品业绩越好？ 博士：博士"新秀"力压群雄！长城基金梁福睿、永赢基金单林夺冠亚！ 公募排排网数据显示，截至9月15日，377位博士基金经理所管的产品今年来收益均值为20.39%，其中仅14位博士基金经理出现年内负收益；表现稍有落后 的是105位本科学历基金经理，今年来收益均值为11.40%。今年整体收益来看：博士基金经理＞硕士基金经理＞本科基金经理。 公募排排网公众号 数据来源:整理自公募排排网,截至日期:2025年9月 收益按旗下基金产品规模加权统计。 公募排排网数据显示，截至9月15日，博士学历的基金经理共有377位，他们的基金经理平均从业年限为5.52年，其中从业年限最长的是知名基金经理朱少 醒，高达19.85年。业绩方面来看，今年来他们的收益均值高达20.39%，位 ...

Core Viewpoint - The article analyzes the performance of mutual fund managers based on their educational backgrounds, revealing that higher educational qualifications correlate with better fund performance in 2023 [3][5][8]. Summary by Sections Doctorate Fund Managers - There are 377 doctorate fund managers, with an average return of 20.39% this year, and only 14 have negative returns [3][5]. - The top three performing doctorate fund managers are Liang Furui from Great Wall Fund, Dan Lin from Yongying Fund, and Qi Nong from Huabao Fund, with returns of 115.48%, 96.43%, and 93.12% respectively [5][6]. - Liang Furui's representative product, Great Wall Medical Industry Selected Mixed Fund A, achieved a return of 113.60% against a benchmark of 22.49% [6][7]. Master's Fund Managers - There are 3,375 master's fund managers, with an average return of 16.93% this year [8]. - The top three performing master's fund managers are Ren Jie from Yongying Fund, Leng Wenpeng from CITIC Construction Investment Fund, and Zhou Shanshan from Jiao Yin Shi Luo Fund, with returns of 183.67%, 119.41%, and 116.55% respectively [9][10]. - Ren Jie's representative product, Yongying Technology Selected Mixed Fund A, achieved a return of 186.12% against a benchmark of 37.38% [10]. Bachelor's Fund Managers - There are 105 bachelor's fund managers, with an average return of 11.40% this year [11]. - The top three performing bachelor's fund managers are Bao Jianwen from Caitong Asset Management, Sa Weixu from Guoshou Anbao Fund, and Ye Yong from Wanjia Fund, with returns of 54.48%, 53.80%, and 40.45% respectively [12][13]. - Bao Jianwen's representative product, Caitong Asset Management Digital Economy Mixed Fund A, achieved a return of 71.41% against a benchmark of 21.01% [12].

Core Viewpoint - The A-share market has shown a clear bullish trend in 2023, with significant index breakthroughs, leading to impressive performance from many equity fund managers [4][5]. Group 1: Fund Manager Performance - As of August 15, 2023, there are 1,794 public fund managers with performance data, with the majority being new generation managers, achieving an average return of 20.68% for their equity funds [5]. - The performance of fund managers is categorized into three generations: - New Generation (less than 5 years): 901 managers, average return of 20.68% [5]. - Middle Generation (5-10 years): 635 managers, average return of 18.09% [5]. - Old Generation (10 years and above): 258 managers, average return of 16.78% [5]. - The total assets under management (AUM) for these fund managers amount to 55,735.04 billion [5]. Group 2: Top Fund Managers - The top five fund managers from the new generation include: - Liang Furui from Changcheng Fund with a return of 137.72% and AUM of approximately 1.1 billion [6][8]. - Chu Kefa and Ren Jie from Yongying Fund with returns of 122.30% and 108.97% respectively [6][9]. - The top five fund managers from the middle generation include: - Leng Wenpeng from CITIC Construction Investment Fund with a return of 104.73% and AUM of nearly 300 million [10][12]. - The top five fund managers from the old generation include: - Zhou Sicong from Ping An Fund with a return of 90.96% and AUM exceeding 3 billion [13][15]. Group 3: Investment Strategies - Liang Furui employs a unique three-cycle strategy focusing on demand and matching companies with demand cycles, particularly in the innovative drug sector [8]. - Chu Kefa combines quantitative risk control with active stock selection, favoring leading commercial companies and those with technological breakthroughs [9]. - Leng Wenpeng focuses on "specialized, refined, unique, and innovative" companies listed on the Beijing Stock Exchange [12]. - Zhou Sicong emphasizes a three-dimensional screening approach for innovative drug investments, predicting significant industry growth in 2025 [16].

Group 1 - In the first seven months of the year, 7656 out of 8237 mixed funds with comparable performance saw an increase in net value, representing 92.95% of the total [1] - Eight mixed funds achieved a growth rate exceeding 100%, primarily focusing on investments in pharmaceutical companies [1] - The top-performing mixed funds include Changcheng Pharmaceutical Industry Select Mixed Fund A and C, with returns of 127.05% and 126.36% respectively [1] Group 2 - The other six mixed funds with growth rates over 100% include Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund A, Yongying Pharmaceutical Innovation Select Mixed Fund A and C, and others, with returns ranging from 102.09% to 113.51% [2] - Yongying Pharmaceutical Innovation Select Mixed Fund A and C, established on November 22, 2022, reported returns of 90.60% and 88.63% respectively [2] - The top holdings of Yongying Pharmaceutical Innovation Select Mixed Fund A and C include companies like Innovent Biologics and BeiGene [2] Group 3 - The worst-performing mixed fund in the first seven months was Qianhai Kaiyuan Artificial Intelligence Theme Mixed Fund A, with a return of -19.15% [3] - This fund, established on May 4, 2016, has a cumulative return of 20.46% since inception [3] - The fund's focus in the second quarter was on stocks in the electronics and communication sectors related to edge AI [3]

Market Performance - The Shanghai Composite Index reached a peak of 3636 points in July, marking a monthly increase of 3.74%, the largest single-month gain of the year [1] - Active equity funds focused on innovative pharmaceuticals have seen significant returns, with five products doubling their returns year-to-date as of July 31 [1] Fund Performance - The top-performing mixed fund, Changcheng Pharmaceutical Industry Select, achieved a year-to-date return of 127.05%, leading the mixed fund performance rankings [2][3] - Other notable mixed funds include Zhongyin Hong Kong Stock Connect Pharmaceutical and Yongying Pharmaceutical Innovation, both exceeding 100% year-to-date returns [2] Fund Manager Insights - The Changcheng Pharmaceutical Industry Select fund, managed by Liang Furui, has a diversified portfolio that includes innovative drugs, traditional Chinese medicine, and diagnostic reagents [3] - Liang Furui anticipates that the innovative drug sector will continue to grow, focusing on overseas licensing and domestic sales expansion in the third quarter [4] Sector Analysis - The mixed fund Yongying Technology Select, representing the technology theme, recorded a year-to-date increase of 94%, primarily investing in leading optical module companies [6] - The stock fund Hua'an Pharmaceutical Bio topped the stock fund performance list with a year-to-date return of 105%, followed by Jiasheng Mutual Selection and Fortune Pharmaceutical Innovation, both exceeding 90% [9] Underperforming Funds - The mixed fund Qianhai Kaiyuan Artificial Intelligence experienced a significant decline, with a year-to-date drop of 19.15%, leading the underperforming fund list [7][8] - Other mixed funds with notable declines include Xinyuan Consumer Selection and Vanguard Gathering, with decreases of 17% and 13%, respectively [8] Investment Strategies - The fund manager Jin Zicai of the Caitong Integrated Circuit Industry fund reported a monthly return of over 31% in July, indicating a turnaround after a poor performance earlier in the year [10][11] - Jin Zicai's strategy includes significant adjustments in the second quarter, focusing on stocks in the optical module and PCB sectors, which are expected to benefit from ongoing demand in overseas markets [12]

7月30日，A股三大股指走势分化，交易行情数据显示，截至下午收盘，上证综指、深证成指、创业板 指分别报收3615.72点、11203.03点、2367.68点，分别涨0.17%、-0.77%、-1.62%。但从年内涨幅来看， A股三大股指均上涨，分别涨7.88%、7.57%、10.56%。 在大盘走势向上的背景下，部分权益类基金的年内表现也颇为亮眼。同花顺iFinD数据显示，截至7月29 日，年内已有23只"翻倍基"。其中，前十大重仓股中均含医药板块个股的汇添富香港优势精选混合 （QDII）C以高达139.12%的年内收益率暂时领先其余产品。汇添富香港优势精选混合（QDII）A、长 城医药产业精选混合发起式A则紧随其后，年内收益率分别为138.9%、129.35%。 包括上述产品在内，年内23只"翻倍基"中，共有17只为创新药、医药相关产品，占比超七成，同时包揽 年内"翻倍基"前15名。还有长城医药产业精选混合发起式C、中银港股通医药混合发起A/C、永赢医药 创新智选混合发起A/C、华安医药生物股票发起式A/C、汇添富国证港股通创新药ETF、万家中证港股 通创新药ETF、广发中证香港创新药ETF（QDII）、 ...

Core Viewpoint - The article discusses the recent performance of the A-share market, highlighting a recovery in the Shanghai Composite Index after a political bureau meeting that released positive signals for the economy and investment opportunities in the innovative pharmaceutical sector [1][2][8]. Group 1: A-share Market Performance - The A-share market experienced a pullback but rebounded in the afternoon, with the Shanghai Composite Index closing in the green, reaching a new high for the year [2][7]. - The market showed significant structural differentiation, with consumer and banking sectors rising while technology and new energy sectors faced declines [6][7]. - The trading volume exceeded 1.84 trillion yuan, indicating active market participation [5]. Group 2: Political Bureau Meeting Insights - The Central Political Bureau meeting emphasized the need to "stably resolve local government debt risks" and introduced a roadmap for "clearing financing platforms," alleviating systemic risk concerns [9]. - The meeting also highlighted the importance of stimulating domestic demand and implementing actions to boost consumption, positively impacting sectors like tourism, retail, and food and beverage [10]. - A focus on technological innovation was reiterated, aiming to foster new competitive industries and integrate technological advancements with industrial development [12]. Group 3: Investment Opportunities in Innovative Pharmaceuticals - A significant number of funds have achieved over 100% returns this year, particularly in the innovative pharmaceutical sector, with several funds listed showing substantial year-to-date performance [17]. - Fund managers suggest a cautious yet optimistic approach to the innovative pharmaceutical sector, advising investors to match risk and return expectations and avoid excessive chasing of high-flying stocks [18][19]. - Key guidelines for selecting funds include focusing on long-term performance stability, understanding investment strategies, and aligning with personal risk preferences [20].

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Insights - The innovative drug sector has seen significant growth this year, with the innovative drug index achieving a cumulative increase of 73.62% year-to-date, and over a quarter of its constituent stocks doubling in price [2][5] - Despite strong performance, there is a notable divergence in fund flows, with some high-performing funds experiencing substantial increases in scale while others face significant reductions [3][4] Fund Performance - Over 98% of pharmaceutical-related theme funds have reported gains this year, with 72 products seeing increases exceeding 50%. Notable performers include Changcheng Pharmaceutical Industry Select Mixed Fund A, which has achieved a return of 116.12% [1][2] - Conversely, some funds have reported negative returns, such as Taikang Medical Health Stock Fund A, which has a year-to-date return of -3.41% [2][3] Fund Flow Dynamics - There has been a significant inflow of funds into certain high-performing products, with some funds experiencing scale increases of over 30 times in a single quarter. For instance, Changcheng Pharmaceutical Industry Select Mixed Fund A's scale surged from 0.36 million to 11.32 million [3][4] - However, more than 30% of funds with returns exceeding 30% have seen a decrease in scale, indicating a complex investor sentiment [3][6] Investor Behavior - Investor behavior reflects a cautious approach, with some choosing to "take profits" amid concerns over short-term volatility. This has led to a significant outflow of over 6.7 billion from related pharmaceutical theme products in the past month [5][6] - Fund managers suggest that the current market adjustment may present a good opportunity for long-term investment in the innovative drug sector, which is believed to be undergoing a significant transformation [6][7] Market Outlook - The innovative drug sector is expected to continue attracting attention, with fund managers focusing on clinical data, overseas licensing, and domestic sales growth as key areas for investment [7]

Group 1 - In the first half of the year, 82.97% of the 8267 comparable mixed funds saw an increase in net value, with 6859 funds rising and 1398 funds declining [1] - Six mixed funds achieved a growth rate exceeding 70%, with the top three being theme products focused on the Beijing Stock Exchange [1][2] - The top-performing fund, China CITIC Bank's Beijing Stock Exchange Selected Two-Year Open Mixed A, recorded a growth of 82.45% and a cumulative net value of 2.3271 yuan since its establishment [1][5] Group 2 - The China CITIC Bank's Beijing Stock Exchange Selected Two-Year Open Mixed Fund A and C are primarily invested in companies that meet the "specialized, refined, unique, and innovative" criteria in various sectors, including medical beauty and automotive parts [2] - The fund manager, Gu Xinfeng, has extensive experience in investment research and management within the industry [2] - Other funds with over 70% growth include Changcheng Medical Industry Selected Mixed Fund A and C, and Bank of China Hong Kong Stock Connect Medical Mixed Fund A, with growth rates of 75.18%, 74.73%, and 70.08% respectively [2][3] Group 3 - The Changcheng Medical Industry Selected Mixed Fund A and C focused on innovative drug sectors, investing in companies with disruptive innovation and those that have commercialized their products [3] - The fund manager, Liang Furui, has a background in medical research and has been with Changcheng Fund Management since 2019 [3] - Four funds from Caitong Fund Management Company were among the top ten funds with the largest declines, each dropping over 16% [3][4]